PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15380039-6 2004 The penetration of NBI-31772 into cartilage was measured by its ability to displace 125I-labeled IGF-1 from cartilage IGFBPs. Iodine-125 84-88 insulin like growth factor 1 Homo sapiens 97-102 16595699-6 2006 However, specific 125I-labeled IGF-I binding and the calculated receptor concentration were significantly elevated in pheochromocytomas as compared with normal adrenomedullary cells (58.3 +/- 5 vs 24.3 +/- 12 nmol/kg protein; P < 0.05). Iodine-125 18-22 insulin like growth factor 1 Homo sapiens 31-36 15380039-8 2004 NBI-31772 inhibited the binding of 125I-labeled IGF-1 to IGFBP-3 at nanomolar concentrations. Iodine-125 35-39 insulin like growth factor 1 Homo sapiens 48-53 10218991-7 1999 IGFBP-5 protein in tumor extracts bound 125I-labeled IGF-I in ligand blot assays and the amounts of IGFBP-5 measured by immunoblotting paralleled the levels of IGFBP-5 mRNA. Iodine-125 40-44 insulin like growth factor 1 Homo sapiens 53-58 9886819-9 1999 Binding experiments with 125I-labeled ovine FSH-20 in IGF-I (100 ng/ml)-treated granulosa cells showed that FSH binding affinity and receptor number were unchanged by IGF-I treatment. Iodine-125 25-29 insulin like growth factor 1 Homo sapiens 54-59 9164277-2 1997 Considerable evidence, based on direct tracer studies with 125I-labeled IGF-I and measurements of circulating IGF-I concentrations in neonatal animals fed a range of IGF-I doses, indicates that the intestinal absorption of IGF-I and the possible effect on metabolism and somatic growth are negligible. Iodine-125 59-63 insulin like growth factor 1 Homo sapiens 72-77 8804561-4 1996 Serum IGFBP concentrations were assessed by a Western ligand blot procedure using 125I-labeled human IGF-I tracer. Iodine-125 82-86 insulin like growth factor 1 Homo sapiens 101-106 8706031-6 1996 The binding of 125I-labeled IGF-I to the SNU368 cells was 5-fold higher than that of SNU387 cells. Iodine-125 15-19 insulin like growth factor 1 Homo sapiens 28-33 8865245-4 1996 IGF-I and IGF-II, and IGFBPs 1-4, were readily identified by specific immunoassays and/or 125iodine-IGF ligand blotting of simultaneously obtained PD and serum samples from seven CRF children; IGFBP-3 was a major IGFBP in PD as in serum. Iodine-125 90-99 insulin like growth factor 1 Homo sapiens 0-5 7664978-3 1995 We incubated adrenal cells with 50 pM 125I-labeled TGF-beta 1 for 15 min to 3 h at 4 degree C and found that the binding of 125I-labeled TGF-beta 1 increased with time and could be inhibited in a dose-dependent manner by non-labeled TGF-beta 1 (0.05-10 nM), but not with other relevant cytokines: IL6, TNF alpha,IGF-I, IGF-II, TGF-alpha, and EGF. Iodine-125 38-42 insulin like growth factor 1 Homo sapiens 312-317 7496335-8 1995 Strong labeling of cells with 125I-labeled IGF-I was observed in all epiretinal membranes and in liver cells. Iodine-125 30-34 insulin like growth factor 1 Homo sapiens 43-48 1319680-3 1992 Chemical cross-linking with 125I-labeled IGF-I and autophosphorylation with [32P]ATP-labeled proteins of relative molecular weight 135,000 and 95,000 correspond to the known Mr values of the alpha- and the beta-subunits of IGF-I receptors. Iodine-125 28-32 insulin like growth factor 1 Homo sapiens 41-46 8163493-7 1994 The rate of 125I-labeled IGF-1 internalization by transfectants overexpressing the wild type IGF-1 receptor was rapid but decreased markedly in the presence of increasing unlabeled IGF-1 (ED50 = 44,000 receptors/cell). Iodine-125 12-16 insulin like growth factor 1 Homo sapiens 25-30 8163493-7 1994 The rate of 125I-labeled IGF-1 internalization by transfectants overexpressing the wild type IGF-1 receptor was rapid but decreased markedly in the presence of increasing unlabeled IGF-1 (ED50 = 44,000 receptors/cell). Iodine-125 12-16 insulin like growth factor 1 Homo sapiens 93-98 8163493-7 1994 The rate of 125I-labeled IGF-1 internalization by transfectants overexpressing the wild type IGF-1 receptor was rapid but decreased markedly in the presence of increasing unlabeled IGF-1 (ED50 = 44,000 receptors/cell). Iodine-125 12-16 insulin like growth factor 1 Homo sapiens 93-98 8163493-9 1994 In contrast, 125I-labeled IGF-1 endocytosis by the mutant kinase-deficient 952STOP cells was slow and not further retarded by unlabeled IGF-1. Iodine-125 13-17 insulin like growth factor 1 Homo sapiens 26-31 1701191-5 1990 Competition studies for the displacement of 125I-labelled IGF-II binding to amniotic fluid by increasing amounts of unlabelled IGF-I or -II, using the charcoal assay, showed that IGF-II was 30-fold more potent than IGF-I. Iodine-125 44-48 insulin like growth factor 1 Homo sapiens 58-63 1709588-4 1991 Dot blot analysis with 125I-labeled recombinant human IGF-I revealed IGF-binding activity in serum-free conditioned medium from 5 of 7 meningiomas, 7 of 8 malignant gliomas, and 3 of 5 other CNS tumors. Iodine-125 23-27 insulin like growth factor 1 Homo sapiens 54-59 1850606-10 1991 Autoradiography with 125I-labeled recombinant IGF-I revealed binding to the IGF-I receptor on the surface of activated AM, and the percentage of labeled cells was reduced with anti-IGF-I receptor monoclonal antibody or excess unlabeled recombinant IGF-I. Iodine-125 21-25 insulin like growth factor 1 Homo sapiens 46-51 1850606-10 1991 Autoradiography with 125I-labeled recombinant IGF-I revealed binding to the IGF-I receptor on the surface of activated AM, and the percentage of labeled cells was reduced with anti-IGF-I receptor monoclonal antibody or excess unlabeled recombinant IGF-I. Iodine-125 21-25 insulin like growth factor 1 Homo sapiens 76-81 1701191-5 1990 Competition studies for the displacement of 125I-labelled IGF-II binding to amniotic fluid by increasing amounts of unlabelled IGF-I or -II, using the charcoal assay, showed that IGF-II was 30-fold more potent than IGF-I. Iodine-125 44-48 insulin like growth factor 1 Homo sapiens 127-132 2557332-3 1989 These three factors are able to compete with 125I-labeled IGF-I for binding to the cell surface with IC50 values equal to approximately 2 (IGF-I), approximately 150 (IGF-II), and approximately 300 nM (insulin). Iodine-125 45-49 insulin like growth factor 1 Homo sapiens 58-63 2170397-2 1990 Relative potencies for the inhibition of 125I-labeled insulin-like growth factor I binding to type I insulin-like growth factor receptors were 1.0:0.20:0.003 for insulin-like growth factor I, the hybrid analog, and insulin, respectively. Iodine-125 41-45 insulin like growth factor 1 Homo sapiens 54-82 2557332-3 1989 These three factors are able to compete with 125I-labeled IGF-I for binding to the cell surface with IC50 values equal to approximately 2 (IGF-I), approximately 150 (IGF-II), and approximately 300 nM (insulin). Iodine-125 45-49 insulin like growth factor 1 Homo sapiens 139-144 2962849-2 1988 The binding of 125I-labeled recombinant (Thr59)IGF-I to the cells was reversible and time, temperature, and pH dependent. Iodine-125 15-19 insulin like growth factor 1 Homo sapiens 47-52 2479022-6 1989 IGF-I and IGF-II but not insulin displaced the binding of 125I-labeled IGF-I or 125I-labeled IGF-II binding to In-IGF-BP. Iodine-125 58-62 insulin like growth factor 1 Homo sapiens 0-5 2479022-6 1989 IGF-I and IGF-II but not insulin displaced the binding of 125I-labeled IGF-I or 125I-labeled IGF-II binding to In-IGF-BP. Iodine-125 58-62 insulin like growth factor 1 Homo sapiens 10-15 2551760-3 1989 Competition studies with 125I-labeled IGF-I and unlabeled IGF-I, IGF-II, and insulin showed the specificity of 125I-IGF-I binding to the IGF-I receptors in adipocytes, membranes, and partially purified detergent-solubilized extracts. Iodine-125 25-29 insulin like growth factor 1 Homo sapiens 38-43 2973422-1 1988 A newly developed immunoprecipitation assay, with 125I-labeled highly purified human placental insulin-like growth factor I (IGF-I) receptor, was used to search for IGF-I-receptor antibodies in human sera. Iodine-125 50-54 insulin like growth factor 1 Homo sapiens 95-123 3033657-4 1987 Conditioned medium from transfected cells inhibits binding of 125I-labeled IGF-I to type I IGF receptors on human placental membranes and to acid-stable human serum carrier proteins. Iodine-125 62-66 insulin like growth factor 1 Homo sapiens 75-80 3711761-6 1986 Half-maximal displacement of 125I-labelled somatomedin C binding occurred at an unlabelled somatomedin C concentration of 0.7 nmol/l. Iodine-125 29-33 insulin like growth factor 1 Homo sapiens 43-56 3019341-1 1986 A monoclonal antibody was identified which equally inhibits 125I-labeled insulin and insulin-like growth factor I (IGF-I) binding to their respective receptors in human IM-9 lymphoid cells and solubilized placenta receptor preparations. Iodine-125 60-64 insulin like growth factor 1 Homo sapiens 115-120 3711761-5 1986 Binding of tracer concentrations of 125I-labelled somatomedin C to human haemangiosarcoma cells was much higher than that of 125I-labelled insulin. Iodine-125 36-40 insulin like growth factor 1 Homo sapiens 50-63 3711761-6 1986 Half-maximal displacement of 125I-labelled somatomedin C binding occurred at an unlabelled somatomedin C concentration of 0.7 nmol/l. Iodine-125 29-33 insulin like growth factor 1 Homo sapiens 91-104 3003744-3 1986 The mouse anti-human IGF-I receptor antibody alpha IR-3 binds with specificity to IGF-I but not to insulin receptors in human placental membranes; it also specifically inhibits the binding of 125I-labeled IGF-I but not 125I-labeled insulin to suspensions of human skin fibroblasts in a dose-dependent manner. Iodine-125 192-196 insulin like growth factor 1 Homo sapiens 21-26 186474-2 1976 Specific binding of 125I somatomedin-C by particulate membranes prepared from fetal organs from a variety of gestational ages almost always exceeds specific 125I insulin binding. Iodine-125 20-24 insulin like growth factor 1 Homo sapiens 25-38 3889029-4 1985 Binding studies using 125I-labeled IGF-I, IGF-II, and insulin revealed specific hormone binding for each ligand to cell membranes derived from four somatotropinomas. Iodine-125 22-26 insulin like growth factor 1 Homo sapiens 35-40 2580858-2 1985 By using disuccinimidyl suberate, we have covalently cross-linked 125I-labeled somatomedin-C (Sm-C)/insulinlike growth factor I to specific binding proteins in human plasma. Iodine-125 66-70 insulin like growth factor 1 Homo sapiens 79-92 4038508-2 1985 Parallel inhibition of binding of 125I-labelled somatomedin-C to antisera raised against somatomedin-C was observed with acid-treated human and chicken plasma. Iodine-125 34-38 insulin like growth factor 1 Homo sapiens 48-61 4038508-2 1985 Parallel inhibition of binding of 125I-labelled somatomedin-C to antisera raised against somatomedin-C was observed with acid-treated human and chicken plasma. Iodine-125 34-38 insulin like growth factor 1 Homo sapiens 89-102 6161369-6 1980 In contrast, sequential addition of platelet-derived growth factor followed by platelet-poor plasma resulted in a 75% increase in 125I-labeled somatomedin-C binding over basal levels during the first 2 hr. Iodine-125 130-134 insulin like growth factor 1 Homo sapiens 143-156